Arbutus Biopharma Corp
$ 4.70
2.17%
26 Feb - close price
- Market Cap 884,690,000 USD
- Current Price $ 4.70
- High / Low $ 4.71 / 4.53
- Stock P/E N/A
- Book Value 0.40
- EPS -0.23
- Next Earning Report 2026-03-26
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.16 %
- ROE -0.46 %
- 52 Week High 5.10
- 52 Week Low 2.70
About
Arbutus Biopharma Corporation, a biopharmaceutical company, is dedicated to the discovery, development, and commercialization of a cure for patients with chronic hepatitis B virus (HBV) infection in the United States. The company is headquartered in Warminster, Pennsylvania.
Analyst Target Price
$5.75
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-26 | 2025-11-13 | 2025-08-06 | 2025-04-30 | 2025-02-26 | 2024-11-06 | 2024-08-01 | 2024-05-02 | 2024-02-29 | 2023-11-07 | 2023-08-03 | 2023-05-04 |
| Reported EPS | 0 | -0.04 | 0.01 | -0.1816 | -0.0999 | -0.09 | -0.11 | -0.1 | -0.12 | -0.12 | -0.1 | -0.1 |
| Estimated EPS | -0.03 | -0.03 | -0.04 | -0.1538 | -0.1168 | -0.09 | -0.1 | -0.11 | -0.12 | -0.11 | -0.11 | -0.14 |
| Surprise | 0.03 | -0.01 | 0.05 | -0.0278 | 0.0169 | 0 | -0.01 | 0.01 | 0 | -0.01 | 0.01 | 0.04 |
| Surprise Percentage | 100% | -33.3333% | 125% | -18.0754% | 14.4692% | 0% | -10% | 9.0909% | 0% | -9.0909% | 9.0909% | 28.5714% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-26 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ABUS
2026-02-20 21:25:00
Arbutus Biopharma has achieved a partial summary judgment against Moderna, barring Moderna's obviousness and derivation defenses related to certain patents. While the court ruled in Arbutus's favor on several points including IPR estoppel and issue preclusion, the dispute regarding enablement will proceed to a jury for resolution. This legal development stems from an SEC filing by Arbutus Biopharma Corp (ABUS).
2026-02-20 05:12:09
Genevant Sciences and Arbutus Biopharma have initiated international patent infringement lawsuits against Moderna in 30 countries, alleging that Moderna's mRNA vaccines infringe on their lipid nanoparticle (LNP) technology patents. These new global actions expand upon existing U.S. litigation, with a jury trial scheduled for September 2025 in Delaware. The legal battles highlight the critical role of LNP technology in mRNA vaccines and could result in significant monetary relief and injunctions against Moderna.
2026-02-18 08:27:44
Arbutus Biopharma (NASDAQ:ABUS) stock briefly traded above its 200-day moving average of $4.28, hitting an intraday high of $4.34 before closing at $4.17. The company has a market capitalization of approximately $802 million and institutional investors hold about 43.8% of its shares. Analyst ratings are mixed, leading to an average "Hold" consensus and a $5.00 price target.
2026-01-19 18:28:22
The European Patent Office has invalidated a key Arbutus Biopharma patent, which benefits Moderna by reducing potential legal challenges in Europe. Arbutus Biopharma, a clinical-stage biopharmaceutical company focused on chronic hepatitis B, faces financial challenges including negative revenue growth and profitability. Despite strong financial strength metrics, investors are advised to consider the company's ongoing patent disputes and sector-specific risks.
2026-01-17 16:28:17
Arbutus Biopharma Corporation's (ABUS) stock fell by 14.04% following the European Patent Office's revocation of a crucial patent, a decision influenced by challenges from Moderna and Merck. This legal setback exacerbates the company's existing financial struggles, which include negative profit margins and a high price-to-sales ratio. Analysts maintain a negative sentiment, citing significant vulnerabilities for ABUS in the competitive biotech landscape.
2026-01-17 02:29:37
Arbutus Biopharma (ABUS) stock has experienced an 11.05% decline amidst market uncertainty regarding strategic shifts and challenges. Despite financial hurdles, the company shows promise through innovative pursuits, strong partnerships, and controlled debt, aiming for wider global reach. Investors remain cautiously optimistic, focusing on risk management and monitoring economic indicators to navigate competitive pressures and ensure sustainable growth.
